Healthcare major Cupid has achieved a major milestone in its diagnostics journey, earning CE certification for its CupiKIT HIV 1&2 Antibody Test Kit and CupiKIT Hepatitis B Surface Antigen (HBsAg) Test Kit.

The European Union In Vitro Diagnostic Regulation (EU 2017/746) certification is recognized as one of the strictest regulatory standards worldwide. With this approval, Cupid can now market its certified products across the European Economic Area (EEA) and other CE-recognized international markets.

“These approvals expand our access to regulated international markets and enhance our ability to participate in large-scale screening and public health programs,” said  Aditya Kumar Halwasiya, Chairman & Managing Director of Cupid Limited.

“The CE (EU IVDR) certification for our HIV 1&2 and Hepatitis B test kits is a meaningful step in strengthening our global diagnostics business. We continue to focus on building a reliable and affordable diagnostics portfolio while scaling our presence across key global regions to address growing healthcare needs.”

The newly certified kits are designed for early detection and large-scale screening programs, particularly across public health initiatives and institutional procurement channels in Europe, Africa, and other emerging markets. CE approval also positions Cupid to participate in government tenders, multilateral agency programs, and regulated international healthcare supply chains where compliance with EU IVDR is mandatory.

This milestone reinforces Cupid Limited’s transition into a broader, innovation-led healthcare and diagnostics platform, complementing its existing maternal health and screening solutions and strengthening its footprint in infectious disease diagnostics.